申请人:Rhone-Poulenc Rorer S.A.
公开号:US05922716A1
公开(公告)日:1999-07-13
Compounds of formula (I): ##STR1## wherein R represents a CR.sub.4 R.sub.5, CHR.sub.6, or C.dbd.R.sub.7 radical and R.sub.3 represents an oxygen atom, salts thereof, the preparation thereof and drugs containing same. The compounds of formula (I) have valuable pharmacological properties and are alpha-amino-3-hydroxy-5-methyl-4-osoxaziepropionic acid (AMPA) receptor antagonists, said receptor also being known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists, and particularly NMDA receptor glycine modulation site ligands.
式(I)化合物:##STR1##其中R表示CR₄R₅、CHR₆或C≡R₇基团,R₃表示氧原子,及其盐类,它们的制备方法以及含有这些化合物的药物。式(I)化合物具有宝贵的药理学特性,是α-氨基-3-羟基-5-甲基-4-异噁唑丙酸(AMPA)受体拮抗剂,该受体也称为quisqualate受体。此外,式(I)化合物是非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂,特别是NMDA受体甘氨酸调节位点的配体。